SAB Biotherapeutics (SABSW) Return on Assets (2021 - 2025)
SAB Biotherapeutics' Return on Assets history spans 5 years, with the latest figure at 0.27% for Q4 2025.
- For Q4 2025, Return on Assets rose 40.0% year-over-year to 0.27%; the TTM value through Dec 2025 reached 0.27%, up 40.0%, while the annual FY2025 figure was 0.44%, 21.0% up from the prior year.
- Return on Assets reached 0.27% in Q4 2025 per SABSW's latest filing, up from 0.4% in the prior quarter.
- In the past five years, Return on Assets ranged from a high of 0.05% in Q3 2021 to a low of 1.2% in Q2 2025.
- Average Return on Assets over 5 years is 0.55%, with a median of 0.55% recorded in 2023.
- The largest YoY upside for Return on Assets was 40bps in 2025 against a maximum downside of -59bps in 2025.
- A 5-year view of Return on Assets shows it stood at 0.17% in 2021, then tumbled by -109bps to 0.36% in 2022, then crashed by -108bps to 0.75% in 2023, then grew by 11bps to 0.67% in 2024, then skyrocketed by 60bps to 0.27% in 2025.
- Per Business Quant, the three most recent readings for SABSW's Return on Assets are 0.27% (Q4 2025), 0.4% (Q3 2025), and 1.2% (Q2 2025).